No Data
No Data
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $30
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $30 to $35
ArriVent BioPharma Is Maintained at Buy by HC Wainwright & Co.
Express News | Arrivent Biopharma, Inc. : H.c. Wainwright Raises Target Price to $30 From $25
Buy Rating Affirmed on ArriVent BioPharma's Strong Clinical Developments and Strategic Partnerships
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $35
No Data